Illinois Municipal Retirement Fund Sells 371 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Illinois Municipal Retirement Fund reduced its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.3% in the 1st quarter, Holdings Channel reports. The fund owned 8,162 shares of the specialty pharmaceutical company’s stock after selling 371 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in ANI Pharmaceuticals were worth $546,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of ANI Pharmaceuticals by 14.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after acquiring an additional 1,972 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of ANI Pharmaceuticals by 6.6% in the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company’s stock worth $762,000 after acquiring an additional 858 shares in the last quarter. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 531 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of ANI Pharmaceuticals by 17,558.4% in the first quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company’s stock worth $6,360,000 after acquiring an additional 94,464 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock worth $1,028,000 after acquiring an additional 417 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the transaction, the vice president directly owned 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. This represents a 0.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Christopher Mutz sold 4,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the transaction, the insider directly owned 107,317 shares of the company’s stock, valued at $6,487,312.65. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,681 shares of company stock valued at $346,854. Insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.1%

ANIP stock opened at $65.29 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98. The stock has a market capitalization of $1.41 billion, a P/E ratio of -51.41 and a beta of 0.57. The business has a 50-day moving average of $63.99 and a 200-day moving average of $61.81. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.33. The company had revenue of $197.12 million during the quarter, compared to analysts’ expectations of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. ANI Pharmaceuticals’s revenue for the quarter was up 43.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.82 earnings per share. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Guggenheim restated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. Wall Street Zen downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Truist Financial increased their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a report on Monday, April 21st. Finally, JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.